Latest Funding Agreements News

Javelin Minerals has locked in a $25 million mining and funding agreement with MEGA Resources, boosting its Eureka Gold Project resources and setting sights on production by mid-2026. The company also raised $4.5 million to accelerate exploration at its key WA gold assets.

Emyria has secured a multi-year funding extension with Medibank to launch its Empax mental health programs in Brisbane, marking a key step in its national expansion. This insurer-backed initiative aims to improve access to treatment for complex conditions like treatment-resistant depression and PTSD.

Nova Minerals’ U.S. subsidiary has won a $43.4 million award from the U.S. Department of War to accelerate production of military-grade antimony trisulfide at its Alaska Estelle Project, aiming to strengthen domestic critical mineral supply.

Harvest Technology Group has inked a $6 million convertible securities funding deal with RiverFort Global Capital, providing immediate working capital and a framework for future financing to accelerate its Nodestream platform expansion.

1414 Degrees has returned to trading after issuing 35.7 million shares to US investor Lind Global Fund II, with approval for an additional 14.3 million shares pending at the upcoming AGM.

Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.

Andromeda Metals has responded to ASX queries regarding its commissioned East Coast Research report, clarifying compliance with disclosure rules and differences in project assumptions.

Andromeda Metals has addressed a recent spike in its share price and trading volume, attributing the movement to a newly released research report and an imminent High Purity Alumina scoping study.

Highfield Resources clarifies its financial position amid funding uncertainties, confirming ongoing talks with major investors and a standstill on matured convertible notes. The company maintains its commitment to the Muga Potash Project despite setbacks.

InFocus Group Holdings has locked in up to AUD 1.7 million in potential revenues through new contracts in healthcare and logistics, underpinning its operational expansion in Southeast Asia.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.